Warny M, Vaerman J P, Avesani V, Delmée M
Microbiology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Infect Immun. 1994 Feb;62(2):384-9. doi: 10.1128/iai.62.2.384-389.1994.
This study investigated whether differences in fecal and serum antitoxin A antibody levels may account for the duration of Clostridium difficile-associated diarrhea (CDAD) and the occurrence of relapses. By an enzyme linked-immunosorbent assay, we tested 40 patients with CDAD including 25 patients without immunodeficiency and 15 patients receiving antineoplastic drugs. Two hundred eighty serum samples and 80 normal stool samples were investigated as controls. In nonimmunocompromised patients, serum immunoglobulin (IgG) and fecal IgA antitoxin A antibody titers were significantly higher in patients who suffered a single episode (n = 21) than in those with relapsing CDAD (n = 4) whose titers were at control levels. Of these 25 patients, eight suffered from diarrhea which lasted for more than 2 weeks. These patients had significantly lower serum- and feces-specific antibody levels than the others who presented symptoms of shorter duration. In cytostatic-treated patients, antitoxin A antibody levels were similar to controls, but relapses occurred in a single case. These data suggest an association between a defective humoral response to toxin A and a more severe form of C. difficile infection. They also indicate that other host-related factors control the severity of CDAD and remain to be elucidated.
本研究调查了粪便和血清抗毒素A抗体水平的差异是否可解释艰难梭菌相关性腹泻(CDAD)的病程及复发情况。通过酶联免疫吸附测定法,我们检测了40例CDAD患者,其中包括25例无免疫缺陷患者和15例接受抗肿瘤药物治疗的患者。以280份血清样本和80份正常粪便样本作为对照。在非免疫受损患者中,单次发作患者(n = 21)的血清免疫球蛋白(IgG)和粪便IgA抗毒素A抗体滴度显著高于复发型CDAD患者(n = 4),后者的滴度处于对照水平。在这25例患者中,8例腹泻持续超过2周。这些患者的血清和粪便特异性抗体水平显著低于其他病程较短的患者。在接受细胞抑制治疗的患者中,抗毒素A抗体水平与对照相似,但仅1例出现复发。这些数据表明对毒素A的体液免疫反应缺陷与更严重的艰难梭菌感染形式之间存在关联。它们还表明其他宿主相关因素控制着CDAD的严重程度,有待进一步阐明。